Understanding how different treatments work for myotonic dystrophy type 1
Mechanisms underlying differential efficacy of DM1 therapeutics
This study is looking at different treatment options for myotonic dystrophy type 1 using a special mouse model to see how well they work, so we can find the best ways to help people with this condition in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10992317 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the varying effectiveness of treatments for myotonic dystrophy type 1 (DM1). It utilizes a newly developed mouse model that mimics the human condition, allowing researchers to study the metabolism of expanded CUG mRNA and its impact on disease progression. By examining three therapeutic approaches—antisense oligonucleotides, siRNAs, and phosphoramidite morpholino oligonucleotides—the research aims to identify which strategies hold the most promise for clinical application. This work is crucial for guiding future clinical trials and improving treatment outcomes for patients with DM1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myotonic dystrophy type 1.
Not a fit: Patients with other forms of muscular dystrophy or unrelated neuromuscular disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with myotonic dystrophy type 1.
How similar studies have performed: Previous research has shown promise in using similar therapeutic approaches for other genetic disorders, indicating potential for success in this area as well.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Wang, Eric T — University of Florida
- Study coordinator: Wang, Eric T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.